Search Within

Lindsey Elizabeth Roeker

Formats
  1. Meeting Abstract (80)
  2. Journal Article (41)
  3. Research Letter (11)
  4. Review (5)
  5. Editorial (4)
  6. Book Section (1)
Groups
  1. Department of Medicine (142)
  2. Hematologic Malignancies, Division of (142)
  3. Center for Hematologic Malignancies (108)
  4. Adult Leukemia (104)
  5. GME, Medicine (43)
  6. Graduate Medical Education (43)

More Groups

People
  1. Anthony Mato (94)
  2. Meghan Thompson (37)
  3. Andrew Zelenetz (34)
  4. Omar Abdel-Wahab (16)
  5. Mark Geyer (15)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (11)
  2. 2024 (20)
  3. 2023 (24)
  4. 2022 (24)
  5. 2021 (21)
  6. 2020 (21)

More Years

Publications
  1. Blood (58)
  2. Leukemia and Lymphoma (11)
  3. Blood Advances (7)
  4. Clinical Lymphoma, Myeloma and Leukemia (7)
  5. American Journal of Hematology (6)
  6. British Journal of Haematology (6)

More Publications

Publishers
  1. American Society of Hematology (66)
  2. Taylor & Francis Group (11)
  3. Elsevier Inc. (8)
  4. John Wiley & Sons (7)
  5. American Association for Cancer Research (6)
  6. American Society of Clinical Oncology (6)

More Publishers

Results (142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia
    Meeting Abstract

    Roeker, L. E.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies
    Meeting Abstract

    Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Lewis, D. J.; Ghia, P.; Shah, N. N.; Coombs, C. C.; Cheah, C. Y.; Lamanna, N.; Rhodes, J. M.; Hoffmann, M.; Ma, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib; A next generation; Highly selective; Non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Weirda, W. G.; Cheah, C. Y.; Roeker, L. E.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Review

    Ryan, C. E.; Davids, M. S.; Hermann, R.; Shahkarami, M.; Biondo, J.; Abhyankar, S.; Alhasani, H.; Sharman, J. P.; Mato, A. R.; Roeker, L. E.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
    Meeting Abstract

    Roeker, L. E.; Alencar, A. J.; Murthy, G. S. G.; Hoffmann, M. S.; Pagel, J. M.; Patel, V.; Pauff, J. M.; Zinzani, P. L.; Le Gouill, S.; Mato, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Novel-agent combination therapies in chronic lymphocytic leukemia: The law of relative contributions
    Editorial

    Mato, A. R.; Roeker, L. E.
    Haematologica (2022)

    Fulltext@MSK | Save